Noncovalent Functionalization of Carbon Nanovectors with an Antibody Enables Targeted Drug Delivery
- 7 July 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 5 (8) , 6643-6650
Abstract
Current chemotherapeutics are characterized by efficient tumor cell-killing and severe side effects mostly derived from off-target toxicity. Hence targeted delivery of these drugs to tumor cells is actively sought. We previously demonstrated that poly(ethylene glycol)-functionalized carbon nanovectors are able to sequester paclitaxel, a widely used hydrophobic cancer drug, by simple physisorption and thereby deliver the drug for killing of cancer cells. The cell-killing when these drug-loaded carbon nanoparticles were used was equivalent to when a commercial formulation of paclitaxel was used. Here we show that by further mixing the drug-loaded nanoparticles with Cetuximab, a monoclonal antibody that recognizes the epidermal growth factor receptor (EGFR), paclitaxel is preferentially targeted to EGFR+ tumor cells in vitro. This supports progressing to in vivo studies. Moreover, the construct is unusual in that all three components are assembled through noncovalent interactions. Such noncovalent assembly could enable high-throughput screening of drug/antibody combinations.Keywords
This publication has 29 references indexed in Scilit:
- Effective Drug Delivery, In Vitro and In Vivo, by Carbon-Based Nanovectors Noncovalently Loaded with Unmodified PaclitaxelACS Nano, 2010
- Radiofrequency field‐induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticlesCancer, 2010
- Nanomedicine—Challenge and PerspectivesAngewandte Chemie International Edition, 2009
- Targeted Killing of Cancer Cellsin Vivoandin Vitrowith EGF-Directed Carbon Nanotube-Based Drug DeliveryACS Nano, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Biopharmaceutical challenges associated with drugs with low aqueous solubility—The potential impact of lipid-based formulationsAdvanced Drug Delivery Reviews, 2008
- Soluble Ultra-Short Single-Walled Carbon NanotubesJournal of the American Chemical Society, 2006
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerJournal of Clinical Oncology, 2005
- Core-Cross-Linked Polymeric Micelles as Paclitaxel CarriersBioconjugate Chemistry, 2004
- Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and RadiationCancer Biotherapy and Radiopharmaceuticals, 1999